JP2022540027A - 胃腸健全性状況のための適応介入 - Google Patents
胃腸健全性状況のための適応介入 Download PDFInfo
- Publication number
- JP2022540027A JP2022540027A JP2021577258A JP2021577258A JP2022540027A JP 2022540027 A JP2022540027 A JP 2022540027A JP 2021577258 A JP2021577258 A JP 2021577258A JP 2021577258 A JP2021577258 A JP 2021577258A JP 2022540027 A JP2022540027 A JP 2022540027A
- Authority
- JP
- Japan
- Prior art keywords
- user
- data
- subject
- symptoms
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002496 gastric effect Effects 0.000 title claims description 107
- 230000003862 health status Effects 0.000 title abstract description 53
- 230000003044 adaptive effect Effects 0.000 title description 35
- 238000000034 method Methods 0.000 claims abstract description 140
- 238000011282 treatment Methods 0.000 claims abstract description 46
- 230000003542 behavioural effect Effects 0.000 claims abstract description 43
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 39
- 238000012544 monitoring process Methods 0.000 claims abstract description 37
- 230000001149 cognitive effect Effects 0.000 claims abstract description 32
- 238000012545 processing Methods 0.000 claims abstract description 30
- 238000009225 cognitive behavioral therapy Methods 0.000 claims abstract description 22
- 230000002996 emotional effect Effects 0.000 claims abstract description 18
- 238000012512 characterization method Methods 0.000 claims abstract description 9
- 230000006353 environmental stress Effects 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims description 153
- 208000002193 Pain Diseases 0.000 claims description 80
- 230000036407 pain Effects 0.000 claims description 77
- 230000006399 behavior Effects 0.000 claims description 68
- 208000019901 Anxiety disease Diseases 0.000 claims description 41
- 230000036506 anxiety Effects 0.000 claims description 41
- 238000004891 communication Methods 0.000 claims description 33
- 238000012549 training Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 20
- 230000009471 action Effects 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 230000007613 environmental effect Effects 0.000 claims description 16
- 230000004048 modification Effects 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 230000005540 biological transmission Effects 0.000 claims description 13
- 230000008451 emotion Effects 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 11
- 230000001747 exhibiting effect Effects 0.000 claims description 9
- 238000013507 mapping Methods 0.000 claims description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 229940124575 antispasmodic agent Drugs 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 230000013872 defecation Effects 0.000 claims description 3
- 238000002483 medication Methods 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 239000003467 chloride channel stimulating agent Substances 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 229940125722 laxative agent Drugs 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000003014 reinforcing effect Effects 0.000 claims description 2
- 230000003997 social interaction Effects 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 238000000844 transformation Methods 0.000 claims 1
- 230000036541 health Effects 0.000 description 70
- 230000000694 effects Effects 0.000 description 46
- 230000008569 process Effects 0.000 description 31
- 238000007726 management method Methods 0.000 description 29
- 230000010485 coping Effects 0.000 description 25
- 230000006870 function Effects 0.000 description 23
- 230000002452 interceptive effect Effects 0.000 description 22
- 230000007958 sleep Effects 0.000 description 21
- 208000002551 irritable bowel syndrome Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000003993 interaction Effects 0.000 description 19
- 230000035882 stress Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 230000036651 mood Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000004422 calculation algorithm Methods 0.000 description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000001994 activation Methods 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 230000037361 pathway Effects 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 206010054089 Depressive symptom Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000002787 reinforcement Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010002869 Anxiety symptoms Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 230000004630 mental health Effects 0.000 description 6
- 230000006855 networking Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 208000024335 physical disease Diseases 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 230000011273 social behavior Effects 0.000 description 5
- 230000036642 wellbeing Effects 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 4
- 235000020805 dietary restrictions Nutrition 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 230000010391 action planning Effects 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036640 muscle relaxation Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000007415 Anhedonia Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 206010042209 Stress Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006998 cognitive state Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008921 facial expression Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 238000003064 k means clustering Methods 0.000 description 2
- 238000009239 mindfulness-based cognitive therapy Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 238000011897 real-time detection Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065369 Burnout syndrome Diseases 0.000 description 1
- 102100024484 Codanin-1 Human genes 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 101100012987 Drosophila melanogaster Flacc gene Proteins 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010058672 Negative thoughts Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- -1 antispasmodics Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007422 cognition related pathway Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000005289 dietary characteristics Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 230000005548 health behavior Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000003058 natural language processing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 238000002369 psychoeducation Methods 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4216—Diagnosing or evaluating gastrointestinal ulcers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
1. 利点
2. システム
2.1 システム-オンライン・システム
2.2 システム-クライアント・デバイス及び外部システム
2.3 システム-ネットワーク
2.4 システム-追加態様
3. 方法
3.1 方法-オンボーディング及び予備評価
3.2 方法-介入養生法及びモジュール
3.2.1 介入タイプ及び詳細
3.2.2 実例介入養生法経路
3.3 方法-進展の監視
3.4 方法-正のフィードバック・ループ及び関わりの強化
3.5 方法-追加態様、強化及び予測モデル
4. 結論
Claims (20)
- デバイスとユーザの間のインタフェースを確立するステップと、
前記ユーザの胃腸(GI)状況に関連する信号のセットを前記インタフェースから受け取るステップであって、前記信号のセットが前記ユーザの生理学的データ、行動データ、環境ストレス・データ、感情データ及び認知データを符号化する、ステップと、
モデルを使用して前記信号のセットを処理すると、前記GI状況の特徴付けを決定するステップと、
前記特徴付けに基づいて、構成要素のセットを備える処置の内容を調節するステップであって、前記構成要素のセットが、前記ユーザの状態を改善するための認知行動療法(CBT)構成要素のサブセットを備える、調節するステップと、
前記ユーザに対してパーソナルな処置を施すステップと
を含む方法。 - 前記信号のセット中に捕捉された生理学的データが、症状重症度でタグ付けされた前記ユーザの痛み特性、消化特性及び排便特性を含む、請求項1に記載の方法。
- 前記信号のセット中に捕捉された行動データが、前記ユーザの移動デバイスの通信サブシステムから引き出された前記ユーザの社会的行動特性を含む、請求項2に記載の方法。
- 前記信号のセット中に捕捉された前記ユーザの認知データが、前記ユーザの行動、不安特性、鬱特性及び感情特性と関連する思考パターンを含む、請求項3に記載の方法。
- 前記特徴付けを決定するステップが、前記ユーザに特有の行動のセット、前記ユーザに特有の思考のセット、前記ユーザに特有の生理学的症状のセット、前記ユーザに特有の感情のセット及び前記ユーザに特有の環境トリガの間の流れのネットワークを伴うマッピングを戻すステップを含み、戻される出力は、前記ネットワークの流れを崩壊させて、前記ユーザの症状の低下に寄与するように構成される、請求項4に記載の方法。
- ある形態の前記GI状況を示すユーザのセットからの生理学的データ、行動データ、環境ストレス・データ、感情データ及び認知データを含む集合体データセットに第1のセットの変換を適用すると、組合せデータセットを生成するステップと、
前記ユーザのセットに適用されたCBT構成要素の前記サブセットと関連する処置成果ラベルを含む処置データセットを収集するステップと、
前記組合せデータセット及び前記処置データセットを含む第1の訓練データセットを生成するステップと、
前記第1の訓練データセットを使用して前記モデルを訓練するステップと
をさらに含む、請求項1に記載の方法。 - 前記モデルが、前記ユーザの生理学的データ、行動データ、環境ストレス・データ、感情データ及び認知データのうちの少なくとも1つと関連するデータ・オブジェクトを受け取り、また、効能インジケータでタグ付けされた処置副構成要素の選択を含む出力のセットを戻すためのアーキテクチャを含み、前記方法が、前記モデルによって戻された前記選択に基づいて前記処置の内容を調節するステップをさらに含む、請求項6に記載の方法。
- CBT構成要素の前記サブセットが、前記GI状況を有するユーザの腸及び神経学的アクティビティを、痛み管理療法、社会的行動訓練、認知柔軟性演習及び行動レパートリー変更を介して調整するための材料と共に、前記ユーザのクライアント・デバイスを介して付与される処方箋デジタル療法(PDT)を含む、請求項1に記載の方法。
- 前記処置が、抗生物質、抗鬱剤、鎮痙薬、5-ヒドロキシトリプタミン4アゴニスト、緩下剤、下痢止め投薬、プロバイオティク及び選択的C-2塩化物チャネル・アクチベータのうちの少なくとも1つを含む非CBT構成要素のサブセットをさらに備える、請求項8に記載の方法。
- 前記処置の内容を調節するステップが、戻された前記モデルの出力に基づいて、前記ユーザに提供される非CBT構成要素の前記サブセットの量に対して前記PDTの量を調整するステップを含む、請求項9に記載の方法。
- 前記処置を提供するステップが、前記ユーザの痛み症状の変化の監視と連携して、前記ユーザの環境における環境制御デバイスの活性化を調整するための命令を生成するステップであって、それにより前記ユーザの前記GI状況に関連する痛み強度及び継続期間の調整をもたらす、ステップを含む、請求項1に記載の方法。
- 前記環境制御デバイスが、前記ユーザの前記環境における、音響出力、熱パラメータ調整、視覚的に観察される出力、触覚出力及び光出力のうちの少なくとも1つのための動作モードを備える、請求項11に記載の方法。
- 前記処置を提供するステップが、前記ユーザの生理学的症状の変化の監視と連携して、前記ユーザと関連する実体に伝送するためのスクリプト通信を生成するステップであって、それにより前記GI状況に起因する、前記ユーザを伴う有害な社会的対話を防止する、ステップを含む、請求項1に記載の方法。
- 前記インタフェースを介して、前記ユーザの動機付け及び強化状況依存性並びに行動を特徴付けている報酬感応性データセットを受け取るステップ、及び前記モデルを使用して前記報酬感応性データセットを処理すると、前記処置の態様を調節するステップをさらに含む、請求項13に記載の方法。
- ユーザとのインタフェースを提供する入力デバイスと、
前記入力デバイスと通信し、命令が記憶されている非一時的コンピュータ可読媒体を備える、処理サブシステムと、
を備えるシステムであって、前記命令は、前記処理サブシステムによって実行されると、
前記ユーザの胃腸(GI)状況に関連する信号のセットを前記インタフェースから受け取るステップであって、前記信号のセットが前記ユーザの生理学的データ、行動データ、環境ストレス・データ、感情データ及び認知データを符号化する、ステップ、
モデルを使用して前記信号のセットを処理すると、前記GI状況の特徴付けを決定するステップ、
前記特徴付けに基づいて、構成要素のセットを備える処置の内容を調節するステップであって、前記構成要素のセットが、前記ユーザの状態を改善するための認知行動療法(CBT)構成要素のサブセットを備える、調節するステップ、及び
前記ユーザに対して前記処置を施すステップ
のうちの1つ又は複数を実施する、システム。 - 前記ユーザに対して前記処置を施すための動作モードを備える出力デバイスをさらに備える、請求項15に記載のシステム。
- 前記出力デバイス及び前記処置のうちの少なくとも1つが、前記ユーザの前記GI状況が診断されると利用することができる処方箋療法として前記ユーザに提供される、請求項16に記載のシステム。
- 前記出力デバイスが前記ユーザの環境における環境制御デバイスを備え、前記処理サブシステムが、前記ユーザの痛み症状の変化の監視と連携して前記動作モードを調整するための命令をさらに含み、それにより前記ユーザの前記GI状況に関連する痛み強度及び継続期間の調整をもたらし、前記動作モードが、前記環境における、音響出力、熱パラメータ調整、視覚的に観察される出力、触覚出力及び光出力のうちの少なくとも1つを提供する、請求項17に記載のシステム。
- 前記出力デバイスが、前記ユーザと、前記ユーザに関連する実体との間で通信を伝送するためのアーキテクチャを備える通信デバイスを備え、前記処理サブシステムが、前記ユーザの生理学的症状の変化の監視と連携して、前記ユーザに関連する実体に伝送するためのスクリプト通信を生成するための命令をさらに含む、請求項17に記載のシステム。
- 前記入力デバイスが、前記ユーザと通信し、また、前記GI状況を有する前記ユーザから生理学的データを生成するように構成された生物測定学センサのセットを備える、請求項15に記載のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867275P | 2019-06-27 | 2019-06-27 | |
US62/867,275 | 2019-06-27 | ||
PCT/US2020/038605 WO2020263694A1 (en) | 2019-06-27 | 2020-06-19 | Adaptive interventions for gastrointestinal health conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022540027A true JP2022540027A (ja) | 2022-09-14 |
Family
ID=74044818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021577258A Pending JP2022540027A (ja) | 2019-06-27 | 2020-06-19 | 胃腸健全性状況のための適応介入 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200411185A1 (ja) |
EP (1) | EP3989906A4 (ja) |
JP (1) | JP2022540027A (ja) |
KR (1) | KR20220034806A (ja) |
CN (1) | CN114502127A (ja) |
AU (1) | AU2020304353A1 (ja) |
CA (1) | CA3142951A1 (ja) |
WO (1) | WO2020263694A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11684299B2 (en) | 2019-12-17 | 2023-06-27 | Mahana Therapeutics, Inc. | Method and system for remotely monitoring the psychological state of an application user using machine learning-based models |
US11967432B2 (en) | 2020-05-29 | 2024-04-23 | Mahana Therapeutics, Inc. | Method and system for remotely monitoring the physical and psychological state of an application user using altitude and/or motion data and one or more machine learning models |
US11610663B2 (en) | 2020-05-29 | 2023-03-21 | Mahana Therapeutics, Inc. | Method and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using average physical activity data associated with a set of people other than the user |
US12073933B2 (en) | 2020-05-29 | 2024-08-27 | Mahana Therapeutics, Inc. | Method and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using baseline physical activity data associated with the user |
US12073294B2 (en) * | 2020-07-27 | 2024-08-27 | Kpn Innovations, Llc. | Method of and system for generating a stress balance instruction set for a user |
US11763928B2 (en) * | 2020-12-29 | 2023-09-19 | Kpn Innovations, Llc. | System and method for generating a neuropathologic nourishment program |
US20210275094A1 (en) * | 2021-01-15 | 2021-09-09 | Accentus-Ludus, Llc | System, apparatus, and method of accelerated training for performance under stress |
WO2022200985A1 (en) * | 2021-03-22 | 2022-09-29 | Ayur.Ai (Opc) Private Limited | Smart wearable device and method for estimating traditional medicine system parameters |
AU2022270722A1 (en) * | 2021-05-07 | 2023-12-14 | Atai Therapeutics Inc. | Systems, devices, and methods for event-based knowledge reasoning systems using active and passive sensors for patient monitoring and feedback |
CN113239050B (zh) * | 2021-06-17 | 2024-07-23 | 上海鼎博医疗科技有限公司 | 医疗与心理数据管理系统、方法、设备和存储介质 |
WO2023133573A1 (en) * | 2022-01-10 | 2023-07-13 | Mahana Therapeutics, Inc. | Methods and systems for treating chronic pain conditions using digital therapeutics in combination with other therapies |
KR20230169751A (ko) | 2022-06-09 | 2023-12-18 | 주식회사 오디엔 | 디지털 치료제 관리 시스템 및 그 동작방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150190634A1 (en) * | 2014-01-06 | 2015-07-09 | Ohio State Innovation Foundation | Neuromodulatory systems and methods for treating functional gastrointestinal disorders |
US20160120732A1 (en) * | 2014-09-26 | 2016-05-05 | ColoWrap, LLC. | Therapeutic undergarments for the treatment of functional gastrointestinal disorders including irritable bowel syndrome |
WO2017214630A1 (en) * | 2016-06-10 | 2017-12-14 | Biotrak Health, Inc. | Device and system for monitoring and treating muscle tension-related medical conditions |
US20180330824A1 (en) * | 2017-05-12 | 2018-11-15 | The Regents Of The University Of Michigan | Individual and cohort pharmacological phenotype prediction platform |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2709641B1 (en) * | 2011-05-16 | 2017-12-13 | Vital Food Processors Limited | A dietary supplement |
EP2709522B1 (en) * | 2011-05-20 | 2016-09-14 | Nanyang Technological University | System for synergistic neuro-physiological rehabilitation and/or functional development |
US9427185B2 (en) * | 2013-06-20 | 2016-08-30 | Microsoft Technology Licensing, Llc | User behavior monitoring on a computerized device |
US10325685B2 (en) * | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
AU2016205850B2 (en) * | 2015-01-06 | 2018-10-04 | David Burton | Mobile wearable monitoring systems |
CN108780663B (zh) * | 2015-12-18 | 2022-12-13 | 科格诺亚公司 | 数字个性化医学平台和系统 |
US10231664B2 (en) * | 2016-05-26 | 2019-03-19 | Raghav Ganesh | Method and apparatus to predict, report, and prevent episodes of emotional and physical responses to physiological and environmental conditions |
WO2018027080A1 (en) * | 2016-08-03 | 2018-02-08 | Akili Interactive Labs, Inc. | Cognitive platform including computerized evocative elements |
-
2020
- 2020-06-19 WO PCT/US2020/038605 patent/WO2020263694A1/en active Application Filing
- 2020-06-19 AU AU2020304353A patent/AU2020304353A1/en active Pending
- 2020-06-19 JP JP2021577258A patent/JP2022540027A/ja active Pending
- 2020-06-19 US US16/906,085 patent/US20200411185A1/en not_active Abandoned
- 2020-06-19 EP EP20833527.3A patent/EP3989906A4/en active Pending
- 2020-06-19 CA CA3142951A patent/CA3142951A1/en active Pending
- 2020-06-19 CN CN202080047132.3A patent/CN114502127A/zh active Pending
- 2020-06-19 KR KR1020227003055A patent/KR20220034806A/ko active Search and Examination
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150190634A1 (en) * | 2014-01-06 | 2015-07-09 | Ohio State Innovation Foundation | Neuromodulatory systems and methods for treating functional gastrointestinal disorders |
US20160120732A1 (en) * | 2014-09-26 | 2016-05-05 | ColoWrap, LLC. | Therapeutic undergarments for the treatment of functional gastrointestinal disorders including irritable bowel syndrome |
WO2017214630A1 (en) * | 2016-06-10 | 2017-12-14 | Biotrak Health, Inc. | Device and system for monitoring and treating muscle tension-related medical conditions |
US20180330824A1 (en) * | 2017-05-12 | 2018-11-15 | The Regents Of The University Of Michigan | Individual and cohort pharmacological phenotype prediction platform |
Non-Patent Citations (1)
Title |
---|
KATIE L. BURKHOUSE,外6名, "NEURAL REACTIVITY TO REWARD AS A PREDICTOR OF COGNITIVE BEHAVIORAL THERAPY RESPONSE IN ANXIETY AND, JPN6023050897, 1 April 2017 (2017-04-01), ISSN: 0005217162 * |
Also Published As
Publication number | Publication date |
---|---|
CN114502127A (zh) | 2022-05-13 |
AU2020304353A1 (en) | 2022-02-17 |
CA3142951A1 (en) | 2020-12-30 |
EP3989906A4 (en) | 2023-07-19 |
WO2020263694A1 (en) | 2020-12-30 |
US20200411185A1 (en) | 2020-12-31 |
EP3989906A1 (en) | 2022-05-04 |
KR20220034806A (ko) | 2022-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200411185A1 (en) | Adaptive interventions for gastrointestinal health conditions | |
US20220028529A1 (en) | Methods and systems for treating gastrointestinal and inflammatory health conditions using prescription digital therapeutics | |
US20220028528A1 (en) | Methods and systems for treating health conditions using prescription digital therapeutics | |
Ng et al. | Self-determination theory applied to health contexts: A meta-analysis | |
US20220028541A1 (en) | Methods and systems for treating gastrointestinal and inflammatory health conditions using prescription digital therapeutics in combination with other therapies | |
Alvarez-Monjarás et al. | Does maternal reflective functioning mediate associations between representations of caregiving with maternal sensitivity in a high-risk sample? | |
Monteiro-Guerra et al. | Breast cancer survivors’ perspectives on motivational and personalization strategies in mobile app–based physical activity coaching interventions: Qualitative study | |
WO2022086781A1 (en) | Methods and systems for treating health conditions using prescription digital therapeutics | |
Lundqvist | Ending an elite sports career: Case report of behavioral activation applied as an evidence-based intervention with a former Olympic athlete developing depression | |
Ollier et al. | Elena+ care for COVID-19, a pandemic lifestyle care intervention: intervention design and study protocol | |
Pemberton et al. | Differential attention as a mechanism of change in parent–child interaction therapy: Support from time-series analysis | |
van Het Schip et al. | Spoken animated self-management video messages aimed at improving physical activity in people with type 2 diabetes: development and interview study | |
Abdulrahman et al. | Changing users’ health behaviour intentions through an embodied conversational agent delivering explanations based on users’ beliefs and goals | |
Tyler et al. | Contemporary self-reflective practices: A large-scale survey | |
WO2022086783A1 (en) | Methods and systems for treating gastrointestinal and inflammatory health conditions using prescription digital therapeutics | |
Hudlicka | Enhancing mindfulness-based cognitive therapy with a virtual mindfulness coach | |
Xuan et al. | Habitpad: a habit-change person-centric healthcare mobile application with machine leaning and gamification features for obesity | |
Costa et al. | The processes of engagement in information-seeking behavior for individuals with diabetes who developed diabetic foot ulcer: A constructivist grounded theory study | |
Chu et al. | CBT Treatment Plans and Interventions for Depression and Anxiety Disorders in Youth | |
WO2022086784A1 (en) | Methods and systems for treating gastrointestinal and inflammatory health conditions using prescription digital therapeutics in combination with other therapies | |
WO2024011105A1 (en) | Methods and systems for treating tinnitus using digital therapeutics | |
Lankheet | Qualitative research into the requirements of a coaching technology for diabetes type 2 patients to motivate them into exercise and nutritional (lifestyle) changes. | |
Caldeira | Self-tracking Technology for Senior Health: Existing Practices and Unmet Needs for Wellness, Self-management, and Recovery | |
WO2023133575A2 (en) | Methods and systems for treating chronic itch conditions using digital therapeutics in combination with other therapies | |
WO2023133573A1 (en) | Methods and systems for treating chronic pain conditions using digital therapeutics in combination with other therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221020 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240312 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240628 |